Trial Profile
A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs LM 11A-31 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker; Proof of concept
- Sponsors PharmatrophiX
- 04 Aug 2022 Subgroup analysis assessing drug effect in older and younger individuals presented at the Alzheimer's Association International Conference 2022
- 04 Oct 2020 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 03 Sep 2020 Status changed from active, no longer recruiting to completed.